OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, headquartered in New York City, with additional offices in various global locations. The firm manages approximately $5 billion in assets and specializes in private equity and venture capital investments across the healthcare sector, including pharmaceuticals, biotechnology, medical devices, and healthcare services. OrbiMed invests in companies at various stages, from early startups to established multinationals, and typically seeks to take majority stakes in its private equity investments. The firm employs fundamental analysis to guide its investment decisions and offers a range of financial services, including debt financing and structured capital, to both public and private healthcare companies. OrbiMed's investment strategy encompasses a broad spectrum of healthcare-related opportunities, targeting investments globally, primarily in North America, Europe, and Asia.
Magenta Medical Ltd., founded in 2012 and based in Kadima, Israel, specializes in developing innovative device solutions for the treatment of acute and chronic heart failure. The company's primary focus is on a temporary venous catheter-based therapy designed specifically for patients experiencing acute decompensated heart failure. By addressing critical needs within this medical field, Magenta Medical aims to improve patient outcomes through its advanced therapeutic technologies.
Caris Life Sciences is a biotechnology company based in Irving, Texas, specializing in precision medicine and cancer treatment. Founded in 1996, the company develops and commercializes advanced diagnostic technologies, including anatomic pathology and molecular profiling, to enhance the understanding of cancer biology. Its services encompass comprehensive molecular analyses of patient samples, integrating genomic, transcriptomic, and proteomic profiling through the Caris Molecular Intelligence platform. This platform aids physicians and cancer patients in making informed and personalized treatment decisions by revealing the molecular blueprint of complex diseases. Caris Life Sciences serves a global customer base through distributors in regions including the United States, Europe, and Australia, and maintains a strategic collaboration with Debiopharm International SA. The company is committed to improving patient outcomes through innovative scientific advancements and a focus on quality care.
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Adaptive Biotechnologies is a commercial-stage company focused on advancing immune-driven medicine by leveraging the biology of the adaptive immune system for disease diagnosis and treatment. Founded in 2009 and headquartered in Seattle, Washington, the company offers a range of products and services, including the immunoSEQ research service and kit, which aids in research and the discovery of diagnostic signals. Its FDA-authorized clonoSEQ diagnostic test is designed for the detection and monitoring of minimal residual disease in patients with specific blood cancers. Additionally, Adaptive Biotechnologies is developing a pipeline of clinical products aimed at diagnosing and treating cancer, autoimmune conditions, and infectious diseases. The company has formed strategic collaborations with notable partners, including Genentech for neoantigen-directed T cell therapies, Microsoft for early disease detection tests from blood samples, and Amgen for therapeutic development related to COVID-19.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
LifeWell
Venture Round in 2022
LifeWell is a new entity formed through the merger of LifeCell’s diagnostics business and MFine.
DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.
Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers.
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns.
Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines.
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).
PierianDx, Inc. is a technology company that develops a genomic software-as-a-service (SaaS) solution designed to manage, analyze, and interpret complex genomic tests for clinical laboratories in the United States. The company offers the Clinical Genomicist Workstation, a platform that streamlines the workflow for patient cases, handling everything from sequencing and analysis to report generation and integration with electronic health records. PierianDx aims to enhance the adoption of genomic sequencing in healthcare, enabling physicians to diagnose and treat patients with cancer and other complex diseases more effectively. The company also provides consulting and technical services to support its clients, which include health systems, children's hospitals, comprehensive cancer centers, and reference laboratories. Founded in 2014 and headquartered in Saint Louis, Missouri, PierianDx has established itself as a trusted source for advanced genomic reporting and decision support in clinical care.
ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in utilizing a proprietary platform that leverages endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in mRNA transcripts. This innovative approach aims to restore the production of functional proteins, addressing various genetic mutations that contribute to diseases. ADARx is developing a pipeline of therapeutics designed to treat a range of conditions, including genetic, cardiometabolic, complement-mediated, and central nervous system diseases, offering potential solutions for previously incurable ailments.
Disc Medicine, Inc. is a biotechnology company focused on developing therapeutics based on human genetics to address ineffective red blood cell production in hematologic diseases. The company specializes in programs targeting the hepcidin metabolism axis for the treatment of disorders related to hepcidin. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine is led by a team of experienced scientists and industry experts, supported by a panel of advisors with a proven history in discovering and developing innovative therapies. The company was established with backing from Atlas Venture, along with contributions from Novo Ventures and Access Biotechnology.
Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focused on creating and commercializing human tissue-based products for regenerative medicine and vascular surgery. Founded in 2004, the company specializes in developing acellular extracellular matrices derived from banked vascular smooth muscle cells, which are decellularized to prevent rejection. These matrices serve as tissue-engineered grafts, providing solutions for patients requiring vascular repair or replacement. Humacyte's innovative biotechnology platform aims to deliver universally implantable bioengineered human tissues and organs, addressing a variety of diseases, injuries, and chronic conditions, ultimately seeking to enhance patient outcomes and transform medical practices.
Miaoshou Doctor is a healthcare service platform founded in 2015 by Tao He and Daoliang Han, based in Beijing. The platform facilitates communication between healthcare professionals and patients, focusing on the management of post-diagnosis outcomes. It enables doctors to actively follow up with patients through additional counseling and prescriptions, enhancing the overall patient care experience. By providing tools for effective interaction, Miaoshou Doctor aims to improve health management for both patients and doctors.
Rimag provides medical imaging service. The company engages in medical imaging center operation, relevant cloud technology development, and talent training. The company was founded in 2014 and is based in Shenzhen, China.
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.
Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
Caris Life Sciences is a biotechnology company based in Irving, Texas, specializing in precision medicine and cancer treatment. Founded in 1996, the company develops and commercializes advanced diagnostic technologies, including anatomic pathology and molecular profiling, to enhance the understanding of cancer biology. Its services encompass comprehensive molecular analyses of patient samples, integrating genomic, transcriptomic, and proteomic profiling through the Caris Molecular Intelligence platform. This platform aids physicians and cancer patients in making informed and personalized treatment decisions by revealing the molecular blueprint of complex diseases. Caris Life Sciences serves a global customer base through distributors in regions including the United States, Europe, and Australia, and maintains a strategic collaboration with Debiopharm International SA. The company is committed to improving patient outcomes through innovative scientific advancements and a focus on quality care.
Arrail Dental Clinic, founded in 1998 and based in Beijing, China, specializes in a comprehensive range of oral health care services. The clinic offers treatments in various areas including endodontics, general dentistry, implants, orthodontics, pediatric dentistry, prosthodontics, and periodontics. Additional services encompass toothache treatment, restoration, tooth whitening, elderly teeth care, and hygiene. With thirty branches established in major cities such as Beijing, Shanghai, Shenzhen, Guangzhou, Xiamen, Hangzhou, and Tianjin, Arrail Dental Clinic caters to both domestic and international clients. The clinic also facilitates online appointment services, enhancing accessibility for patients.
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns.
Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Developer of a computer-assisted radiology technology designed to enhance efficiency and effectiveness in imaging-guided cancer treatment. The company's technology offers a platform that supports a patient-specific, disease-targeted and multi-disciplinary approach to cancer treatment, enabling physicians to use advanced clinical applications, including automated volumetric organ segmentation and virtual planning and treatment simulation.
Crossover Health, Inc. is a healthcare provider focused on delivering comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010 and headquartered in Aliso Viejo, California, the company operates health centers in various locations, including Silicon Valley. Crossover Health offers a wide range of services, such as primary care, urgent care, preventive care, chronic disease management, health education, physical therapy, and remote care, among others. By integrating various health and wellness benefits with technology-enabled services, Crossover Health aims to enhance access to care and reduce healthcare costs for companies. The firm collaborates closely with client partners to customize health services based on health analytics, fostering a culture of health ownership among employees while improving both the quality of care and the overall employee experience.
Graphite Bio is a gene editing company focused on targeted DNA integration to address severe diseases. The company employs technology that enables the insertion of new genetic sequences to replace defective genes, repair damaged portions of genes, and insert therapeutic genetic material at specific locations within the genome. This precise approach leverages natural cellular DNA repair mechanisms to enhance the efficiency of gene integration, aiming to correct the underlying causes of various diseases. Founded in 2019 and based in South San Francisco, California, Graphite Bio was previously known as Integral Medicines, Inc. and rebranded in August 2020. The company is committed to advancing gene replacement therapies and potential cures for individuals affected by serious health conditions.
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
AnchorDx is a company focused on advancing precision medicine through its development of next-generation sequencing techniques, particularly utilizing molecular liquid biopsies. This approach offers non-invasive access to genetic information, enabling patients to gain insights into their physiological conditions and prepare for potential future health issues. With a core team boasting over 20 years of experience in cancer genomics, genetics, and bioinformatics, AnchorDx aims to establish itself as a leading global provider of precision medical solutions. The company collaborates with various middle and downstream enterprises, fostering a comprehensive industrial chain that spans from academic research to clinical product transformation. Additionally, AnchorDx has formed partnerships with numerous large-scale third-party inspection agencies, hospitals, and research institutes, contributing to the development of independent intellectual property rights and competitive clinical testing products that deliver accurate and comprehensive services to patients, doctors, and medical institutions.
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing exosome-based therapeutics for the treatment of severe diseases. Founded in 2016, the company leverages its proprietary technology to harness and engineer extracellular vesicles, known as exosomes, for the targeted delivery of nucleic acids and proteins. This innovative approach aims to enhance drug delivery to challenging areas, such as the brain and central nervous system, where conventional therapies often fall short. Evox’s mission is to improve human health by creating novel therapeutics that address significant medical needs, particularly for conditions with limited treatment options. The company has built a comprehensive intellectual property portfolio and is backed by prominent life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based drug delivery.
Miaoshou Doctor is a healthcare service platform founded in 2015 by Tao He and Daoliang Han, based in Beijing. The platform facilitates communication between healthcare professionals and patients, focusing on the management of post-diagnosis outcomes. It enables doctors to actively follow up with patients through additional counseling and prescriptions, enhancing the overall patient care experience. By providing tools for effective interaction, Miaoshou Doctor aims to improve health management for both patients and doctors.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in the development of therapeutic wearable devices aimed at treating chronic neurological and sleep disorders. By focusing on innovative therapies, Noctrix Health seeks to address the unmet needs of patients suffering from these conditions.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
Cytek Biosciences, Inc. specializes in manufacturing and selling innovative flow cytometry tools and equipment for cancer and cell biology research. The company offers advanced instruments such as the Cytek Aurora and Cytek Northern Lights, which are full-spectrum flow cytometers designed for high-resolution and high-sensitivity cell analysis. Additionally, Cytek provides the DxP Athena system, which utilizes its proprietary technology to resolve dim populations in multicolor formats, along with the QbSure quality control program to ensure optimal performance of cytometers. The company also develops proprietary cFluor reagents that enhance the performance of its instruments in complex multicolor environments. Headquartered in Fremont, California, Cytek has expanded its global presence with locations in Maryland, the Netherlands, Japan, and China, aiming to make flow cytometry more accessible for researchers and clinicians worldwide.
Zylox Medical Device Co. was founded in the beautiful city of Hangzhou in 2012 by a group of highly skillful and experienced returnees from the US and Europe. They have on average 5-20 years of working experiences in various functional areas such as research and development, management, and manufacturing in leading device makers including Johnson & Johnson, Medtronic, and Abbott before returning to China. Since its inception, Zylox has developed an increasingly rich product pipeline of interventional and implantable peripheral vascular devices such as PTA balloons, PTA drug-coated Balloons (PTA DCB), superficial femoral artery (SFA) stent, drug-eluting SFA stent, and other vascular accessories. Zylox strives to continuously innovate and provide patients with superior quality medical devices.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Caris Life Sciences is a biotechnology company based in Irving, Texas, specializing in precision medicine and cancer treatment. Founded in 1996, the company develops and commercializes advanced diagnostic technologies, including anatomic pathology and molecular profiling, to enhance the understanding of cancer biology. Its services encompass comprehensive molecular analyses of patient samples, integrating genomic, transcriptomic, and proteomic profiling through the Caris Molecular Intelligence platform. This platform aids physicians and cancer patients in making informed and personalized treatment decisions by revealing the molecular blueprint of complex diseases. Caris Life Sciences serves a global customer base through distributors in regions including the United States, Europe, and Australia, and maintains a strategic collaboration with Debiopharm International SA. The company is committed to improving patient outcomes through innovative scientific advancements and a focus on quality care.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
CoreMap, Inc. develops a diagnostic technology for electrophysiologists for treating atrial fibrillation. It offers CoreMap micro-electrode solution for mapping tissue properties (ability to map sequentially). The company also provides CoreMap ultra-high resolution electrodes reveal the details of activation despite fibrillation. The company was incorporated in 2016 and is based in Winooski, Vermont.
MobileODT Ltd specializes in developing optical diagnostic devices and software focused on early cancer detection, particularly cervical cancer. The company's flagship product, the EVA COLPO, is a portable, internet-connected colposcope that is FDA-cleared and designed for ease of use. MobileODT also offers EVA SANE, a secure platform for managing patient information, and EVA WELL, a digital visualization tool for gynecologic exams. Their offerings include a mobile application for remote image capture and patient tracking, along with a cloud-based portal for collaboration and reporting. In addition, the company provides tools for documenting violence and abuse and plans to expand its product line to cover other medical areas such as ENT and dermatology. Established in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has gained recognition in various markets, particularly the United States, where it is becoming a standard for visual diagnostics in healthcare settings.
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
TytoCare Ltd. is a healthcare technology company that develops handheld devices and applications for on-demand medical examinations and remote diagnoses. Founded in 2012 and based in Netanya, Israel, with an office in New York, the company offers three main telehealth products: TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote care settings. These tools enable users to conduct self-examinations of various health conditions, such as ear infections, respiratory issues, and abdominal pain, by assessing the heart, lungs, skin, throat, ears, and body temperature. The platform facilitates virtual consultations by connecting patients with healthcare professionals, allowing for diagnosis and prescriptions as needed. TytoCare's technology incorporates a cloud-based data repository, analytics, and machine learning algorithms to enhance user experience and diagnostic accuracy. The company has established a strategic partnership with Novant Health to further its mission of making healthcare accessible and convenient.
ReCode Therapeutics is a biopharmaceutical company that focuses on developing precision medicines for pulmonary diseases, particularly targeting rare conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company has created a non-viral lipid nanoparticle platform that facilitates the targeted delivery of genetic therapies. This innovative technology aims to deliver corrective or disease-modifying therapies to specific organs and tissues, addressing the limitations of current gene therapy methods. By improving the precision of drug delivery, ReCode Therapeutics seeks to provide new treatment options for patients with unmet medical needs, particularly in the realm of life-limiting respiratory diseases.
Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.
Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.
Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.
Health Catalyst is a company that specializes in data and analytics technology for healthcare organizations, addressing the challenges posed by the transition from paper to electronic health records. It focuses on organizing, normalizing, and linking disparate health data from various systems, making it easily searchable for all users, including those without technical expertise. Health Catalyst operates through two primary segments: the Technology segment, which is the main revenue driver, offers cloud-based data platforms, analytics applications, and support services, primarily through subscription and licensing agreements. The Professional Services segment provides a combination of analytics, implementation, strategic advisory, and outsourcing services, helping healthcare organizations effectively utilize the technology to improve outcomes and operational efficiency.
Health Catalyst is a company that specializes in data and analytics technology for healthcare organizations, addressing the challenges posed by the transition from paper to electronic health records. It focuses on organizing, normalizing, and linking disparate health data from various systems, making it easily searchable for all users, including those without technical expertise. Health Catalyst operates through two primary segments: the Technology segment, which is the main revenue driver, offers cloud-based data platforms, analytics applications, and support services, primarily through subscription and licensing agreements. The Professional Services segment provides a combination of analytics, implementation, strategic advisory, and outsourcing services, helping healthcare organizations effectively utilize the technology to improve outcomes and operational efficiency.
Third Harmonic Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for severe allergies and inflammation. The company is focused on creating first-in-class oral small-molecule inhibitors targeting the KIT receptor, which plays a crucial role in the survival and function of mast cells—key immune cells involved in allergic responses. Its lead product candidate, THB001, is designed to provide selective inhibition of KIT, while another candidate, THB335, aims to address multiple mast cell-driven inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. Through its research and development efforts, Third Harmonic Bio seeks to advance the management of inflammatory diseases, enhancing patient outcomes and quality of life.
Bellus Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, focused on developing therapeutics for chronic cough and other hypersensitization disorders. Its lead drug candidate, BLU-5937, is an oral small molecule antagonist of the P2X3 receptor, currently undergoing Phase II clinical trials for chronic cough and chronic pruritus. Additionally, the company is advancing KIACTA™, a novel treatment for AA amyloidosis and sarcoidosis, both rare diseases affecting renal and pulmonary functions, respectively. KIACTA™ is in the data review stage following a Phase 3 study. Bellus Health is also developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli, with pre-clinical studies in progress. Furthermore, the company has a research-stage project aimed at treating AL amyloidosis, a condition characterized by the accumulation of amyloid proteins in various organs. Bellus Health is dedicated to addressing unmet medical needs through its innovative drug development pipeline.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on developing innovative T cell engagers to harness the body's immune system for treating cancer and other diseases. Utilizing its proprietary TriTAC platform, the company is working on a pipeline of engineered proteins designed to direct T cells to target and eliminate specific cancer cells. The lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, Harpoon is developing HPN536, which is in Phase I/IIa trials for ovarian cancer and other tumors expressing MSLN, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Founded in 2015 and headquartered in South San Francisco, California, Harpoon Therapeutics has established a collaboration agreement with AbbVie Biotechnology Ltd to further its research efforts.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with significant unmet medical needs. The company, based in Oakland, California, was incorporated in 2016 and is a subsidiary of Zogenix, Inc. Modis Therapeutics is advancing its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapeutic candidate is specifically designed to address thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance, increasing mitochondrial DNA copy number, and enhancing cell function, Modis Therapeutics aims to provide meaningful treatment options that can prolong the lives of affected patients.
SmartZyme Biopharma is a life science company based in Ness Ziona, Israel, that specializes in the development of innovative protein design and engineering solutions. Founded in 2013, the company focuses on enhancing glucose monitoring technologies for individuals with diabetes. It offers a next-generation enzyme specifically designed for improved bio-electrochemical glucose catalysis, which is intended for use in glucose test strips that facilitate self-monitoring of blood glucose levels. Additionally, SmartZyme has developed Go Patch Go, a personalized patient care system aimed at assisting diabetic patients in maintaining balanced glucose levels. The company has also formed a strategic agreement with Hemoshear Therapeutics to further its research and development initiatives. By advancing glucose-sensing capabilities, SmartZyme aims to improve the safety and effectiveness of continuous glucose monitoring devices, eliminating the need for signal mediators and reducing the occurrence of hypoglycemic errors.
Asian Institute of Medical Sciences is a 425 bedded super specialty hospital in Delhi NCR, India which is dedicated to provide accessible, affordable and best available healthcare services in India. Accredited by NABH and NABL, Asian Hospital Faridabad provides preventive, diagnostic, therapeutic, rehabilitative, palliative and supportive services all under one roof and is designed to meet patient care and research requirements of the new millennium. Asian Institute of Medical Sciences offers comprehensive multi-specialty tertiary care facilities through its 14 centres of excellence. - ASIAN CANCER CENTRE - ASIAN CENTRE FOR BONE MARROW TRANSPLANT - ASIAN HEART CENTRE - ASIAN CENTRE FOR ADVANCED SURGERY - ASIAN CENTRE FOR NEUROLOGY AND NEUROSURGERY - ASIAN CENTRE FOR UROLOGY AND KIDNEY TRANSPLANT - ASIAN CENTRE FOR RENAL DISEASES - ASIAN CENTRE FOR BONE AND JOINTS - ASIAN CENTRE FOR ADVANCED IMAGING - ASIAN CENTRE FOR GASTROENTEROLOGY - ASIAN CENTRE FOR MOTHER AND CHILD - ASIAN CENTRE FOR BARIATRIC & METABOLIC SURGERY - ASIAN CENTRE FOR AESTHETIC SURGERY & MEDICINE - ASIAN IVF CENTRE
TytoCare Ltd. is a healthcare technology company that develops handheld devices and applications for on-demand medical examinations and remote diagnoses. Founded in 2012 and based in Netanya, Israel, with an office in New York, the company offers three main telehealth products: TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote care settings. These tools enable users to conduct self-examinations of various health conditions, such as ear infections, respiratory issues, and abdominal pain, by assessing the heart, lungs, skin, throat, ears, and body temperature. The platform facilitates virtual consultations by connecting patients with healthcare professionals, allowing for diagnosis and prescriptions as needed. TytoCare's technology incorporates a cloud-based data repository, analytics, and machine learning algorithms to enhance user experience and diagnostic accuracy. The company has established a strategic partnership with Novant Health to further its mission of making healthcare accessible and convenient.
MobileODT Ltd specializes in developing optical diagnostic devices and software focused on early cancer detection, particularly cervical cancer. The company's flagship product, the EVA COLPO, is a portable, internet-connected colposcope that is FDA-cleared and designed for ease of use. MobileODT also offers EVA SANE, a secure platform for managing patient information, and EVA WELL, a digital visualization tool for gynecologic exams. Their offerings include a mobile application for remote image capture and patient tracking, along with a cloud-based portal for collaboration and reporting. In addition, the company provides tools for documenting violence and abuse and plans to expand its product line to cover other medical areas such as ENT and dermatology. Established in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has gained recognition in various markets, particularly the United States, where it is becoming a standard for visual diagnostics in healthcare settings.
LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and is uniquely suited for the treatment of children as well as adults.
Guardant Health, Inc. is a precision oncology company based in Redwood City, California, specializing in liquid biopsy tests and analytics for cancer detection and treatment. The company provides advanced testing solutions, including Guardant360, a molecular diagnostic test that analyzes numerous cancer-related genes, and GuardantOMNI, which offers a comprehensive gene panel for immuno-oncology research. Additionally, Guardant Health has developed LUNAR-1 for detecting minimal residual disease in cancer survivors and is working on LUNAR-2 for early cancer detection in high-risk individuals. The company also supports biopharmaceutical companies and medical institutions by offering companion diagnostic development, clinical trial referrals, and liquid biopsy testing services. Guardant Health's innovations aim to address unmet needs in oncology and enhance patient health through advanced technology and research collaborations. The company was incorporated in 2011 and continues to lead in liquid-based cancer testing for both clinical and research applications.
Established in 1992 as Suraksha Diagnostics & Eye Centre (P) Ltd. in Kolkata, they started as one of the first diagnostic centers in Kolkata to provide all pathology and radiology services under one roof. This convenience, along with their unwavering commitment to accuracy and service, resulted in steady growth and popularity. Within 3 years they could confidently open a second Center at Siliguri, in North Bengal, which remains the largest such facility in the region, and today serves not only to patients from North Bengal, but also neighbouring States and countries. Since then they have grown steadily across Bengal, Bihar, and Delhi NCR.
Arrowhead Pharmaceuticals is a biotechnology company based in Pasadena, California, focused on developing innovative therapies for intractable diseases with a genetic basis, particularly those involving the overproduction of specific proteins. The company's pipeline includes several RNA interference (RNAi) therapeutic candidates, such as ARO-AAT for liver diseases linked to alpha-1 antitrypsin deficiency, ARO-APOC3 for hypertriglyceridemia, and ARO-HIF2 for clear cell renal cell carcinoma. Other candidates in various stages of clinical trials aim to address conditions like chronic obstructive pulmonary disease, COVID-19, and cardiovascular diseases. Arrowhead has established collaboration agreements with Janssen Pharmaceuticals and Takeda Pharmaceuticals to further advance its RNAi therapeutics targeting liver-expressed genes. The company, originally founded as Arrowhead Research Corporation in 1989, rebranded in 2016 to reflect its focus on pharmaceutical development.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
Response Biomedical Corp. is engaged in the research, development, commercialization, and distribution of diagnostic technologies tailored for medical central-lab testing, point of care (POC) testing, and on-site environmental testing. The company specializes in non-laboratory tests utilizing portable hand-held devices, compact desktop analyzers, and single-use test cartridges. Its RAMP system offers a portable fluorescence immunoassay-based diagnostic technology that combines clinical lab performance with the convenience of dipstick tests. RAMP tests facilitate the early detection of conditions such as heart attacks, congestive heart failure, and infectious diseases like influenza A+B and respiratory syncytial virus. Additionally, the platform is used for environmental detection, including West Nile Virus, and biodefense applications for rapid on-site identification of threats such as anthrax and ricin. Response Biomedical markets its products through distributors across the United States, Asia, Latin and South America, Europe, the Middle East, and Canada, with its headquarters located in Vancouver, Canada.
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns.
Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.
LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and is uniquely suited for the treatment of children as well as adults.
Guardant Health, Inc. is a precision oncology company based in Redwood City, California, specializing in liquid biopsy tests and analytics for cancer detection and treatment. The company provides advanced testing solutions, including Guardant360, a molecular diagnostic test that analyzes numerous cancer-related genes, and GuardantOMNI, which offers a comprehensive gene panel for immuno-oncology research. Additionally, Guardant Health has developed LUNAR-1 for detecting minimal residual disease in cancer survivors and is working on LUNAR-2 for early cancer detection in high-risk individuals. The company also supports biopharmaceutical companies and medical institutions by offering companion diagnostic development, clinical trial referrals, and liquid biopsy testing services. Guardant Health's innovations aim to address unmet needs in oncology and enhance patient health through advanced technology and research collaborations. The company was incorporated in 2011 and continues to lead in liquid-based cancer testing for both clinical and research applications.
SmartZyme Biopharma is a life science company based in Ness Ziona, Israel, that specializes in the development of innovative protein design and engineering solutions. Founded in 2013, the company focuses on enhancing glucose monitoring technologies for individuals with diabetes. It offers a next-generation enzyme specifically designed for improved bio-electrochemical glucose catalysis, which is intended for use in glucose test strips that facilitate self-monitoring of blood glucose levels. Additionally, SmartZyme has developed Go Patch Go, a personalized patient care system aimed at assisting diabetic patients in maintaining balanced glucose levels. The company has also formed a strategic agreement with Hemoshear Therapeutics to further its research and development initiatives. By advancing glucose-sensing capabilities, SmartZyme aims to improve the safety and effectiveness of continuous glucose monitoring devices, eliminating the need for signal mediators and reducing the occurrence of hypoglycemic errors.
TytoCare Ltd. is a healthcare technology company that develops handheld devices and applications for on-demand medical examinations and remote diagnoses. Founded in 2012 and based in Netanya, Israel, with an office in New York, the company offers three main telehealth products: TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote care settings. These tools enable users to conduct self-examinations of various health conditions, such as ear infections, respiratory issues, and abdominal pain, by assessing the heart, lungs, skin, throat, ears, and body temperature. The platform facilitates virtual consultations by connecting patients with healthcare professionals, allowing for diagnosis and prescriptions as needed. TytoCare's technology incorporates a cloud-based data repository, analytics, and machine learning algorithms to enhance user experience and diagnostic accuracy. The company has established a strategic partnership with Novant Health to further its mission of making healthcare accessible and convenient.
Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Laxmi Dental Export Private Limited operates a dental laboratory that specializes in providing dental products and services. The company manufactures prosthodontics and dental cosmetic products, such as porcelain fused to metals, restoration dental materials, ceramic restorations, implant systems, composites, and cast partial dentures. It serves laboratories and dentists worldwide. The company was incorporated in 2004 and is based in Mumbai, India.
GENEWIZ is a leading global genomics service company. A full-service provider, GENEWIZ provides DNA sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory services.
From the company’s founding, GENEWIZ has maintained its unwavering commitment to providing customers with the best value. Excelling in both science and customer support, GENEWIZ is dedicated to accelerating scientific discovery, as well as to developing and delivering innovative solutions for translational medicine and healthcare. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions.
At GENEWIZ, it is their mission to contribute to the advancement of life sciences and technologies. Together with their clients, they can make a difference in the pursuit of scientific discoveries, better healthcare, a greener environment, and abundant food supplies. Their goal is to be the best in the world and the best for the world.
Headquartered in South Plainfield, NJ, GENEWIZ is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.
MID Labs was founded by Dr. Carl Wang in 1981 and has been associated with vitreoretinal surgery from its infancy. Not only has MID Labs invented the tools for modern vitrectomy, but as a company, it has been instrumental in revolutionizing the ophthalmic field through its products. MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.
Invitae is a genetic information company focused on integrating genetic testing into routine medical practice to enhance healthcare quality worldwide. It specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates a wide array of genetic tests into one platform, ensuring faster turnaround times and lower costs compared to traditional single-gene tests. Invitae's test offerings cover various hereditary conditions, including cancers, neurological disorders, cardiovascular diseases, pediatric and metabolic disorders. The company aims to make genetic testing more affordable and accessible, develop a secure infrastructure for genome management, and foster a global community for sharing genetic information to advance scientific research and medical practices. By lowering the barriers to obtaining diagnostic genetic information, Invitae seeks to improve healthcare outcomes for millions of individuals.
Rapid Pathogen Screening, Inc. is a biotechnology company established in 2004 and headquartered in Sarasota, Florida. The company specializes in the development, manufacture, and marketing of rapid point-of-care diagnostic tests for infectious diseases and inflammatory conditions, as well as for bio-terrorism and chemical nerve agent blood toxins. Its key products include AdenoPlus, a test for adenoviral conjunctivitis, and InflammaDry, which is designed for dry eye assessment. These tests are characterized by their high sensitivity and specificity, enabling healthcare professionals to perform them with minimal training and equipment. Rapid Pathogen Screening sells its products through distributors, aiming to improve patient health outcomes while reducing healthcare costs associated with disease diagnosis and treatment.
Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.
Keystone Heart is a developer and manufacturer of medical devices aimed at enhancing patient care in cardiovascular procedures. The company specializes in creating embolic cerebral protection devices designed to safeguard the brain from emboli, thereby minimizing the risk of brain infarcts, stroke, neurocognitive decline, and dementia during procedures such as transcatheter aortic valve replacement and atrial fibrillation ablation. By focusing on the preservation of cerebral function, Keystone Heart aims to improve procedural outcomes and quality of life for patients undergoing structural heart interventions. The company's commitment to innovative technology and clinical research positions it as a potential leader in the field of cerebral protection during cardiac surgeries.
TytoCare Ltd. is a healthcare technology company that develops handheld devices and applications for on-demand medical examinations and remote diagnoses. Founded in 2012 and based in Netanya, Israel, with an office in New York, the company offers three main telehealth products: TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote care settings. These tools enable users to conduct self-examinations of various health conditions, such as ear infections, respiratory issues, and abdominal pain, by assessing the heart, lungs, skin, throat, ears, and body temperature. The platform facilitates virtual consultations by connecting patients with healthcare professionals, allowing for diagnosis and prescriptions as needed. TytoCare's technology incorporates a cloud-based data repository, analytics, and machine learning algorithms to enhance user experience and diagnostic accuracy. The company has established a strategic partnership with Novant Health to further its mission of making healthcare accessible and convenient.
Practice Fusion, Inc. is a cloud-based electronic health records (EHR) company based in San Francisco, California. Founded in 2005, it provides a practice management software platform that includes features such as charting, scheduling, billing, e-Prescribing, lab integrations, and secure messaging. The platform aims to connect a wide range of stakeholders in the healthcare ecosystem, including medical professionals, patients, labs, billers, imaging centers, and life science partners. Additionally, Practice Fusion offers Practice Fusion Insight, a healthcare database designed for medical professionals. The company serves a diverse clientele, including independent practices, small and large medical groups, community organizations, and non-profits. In 2018, Practice Fusion became a subsidiary of Allscripts Healthcare Solutions, further enhancing its capabilities in the electronic health records space.
Amoy Diagnostics Co., Ltd. (AmoyDx) focuses on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS and Super-ARMS technologies, AmoyDx has a market-leading portfolio of molecular diagnostic kits including but not limited to EGFR, RAS, ALK, BRAF, PIK3CA and ROS1 testing kits, which were firstly approved by CFDA and CE certified. In European EMQN and Chinese PQCC quality control programs, AmoyDx is the NO.1 testing kit supplier for some years and always achieves the highest accuracy rate. Nowadays AmoyDx serves an extensive domestic and international oncology network reaching over 300 hospitals in China and 50 countries all over the world. Every year hundreds of thousands of cancer patients benefit from AmoyDx products.
Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.
Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conducting pilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company focused on developing therapies for cardiovascular disease. The company specializes in nitroxyl technology, which is aimed at addressing areas of cardiovascular treatment where existing therapies are lacking or ineffective. Cardioxyl has developed a robust portfolio of pre-clinical and clinical candidates, with its lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, a prevalent condition among patients over 65 years of age that often leads to hospitalization. Through its innovative approach, Cardioxyl aims to enhance treatment options for patients suffering from cardiovascular diseases.
Whale Imaging Inc. manufactures medical devices, including surgical imaging systems and ultrasound systems. The company offers products, such as G-Arm Products, including G-Arm B6 Duo, and G-Arm GXi 2; and Portable Ultrasound, including Lambda P9, and Sigma P5. It also provides training, preventative maintenance, and support services. Imaging Inc. was incorporated in 1998 and is based in Waltham, Massachusetts with its marketing and Research and Development (R&D) facilities at Boston, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.